Bryn Mawr Capital Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $410K | Hold |
1,809
| – | – | 0.02% | 323 |
|
|
2026
Q1 | $312K | Hold |
1,809
| – | – | 0.02% | 346 |
|
|
2025
Q4 | $361K | Hold |
1,809
| – | – | 0.02% | 327 |
|
|
2025
Q3 | $283K | Hold |
1,809
| – | – | 0.01% | 354 |
|
|
2025
Q2 | $274K | Sell |
1,809
-5
| -0.3% | -$667 | 0.02% | 356 |
|
|
2025
Q1 | $273K | Buy |
1,814
+5
| +0.3% | +$838 | 0.02% | 333 |
|
|
2024
Q4 | $334K | Hold |
1,809
| – | – | 0.02% | 333 |
|
|
2024
Q3 | $356K | Hold |
1,809
| – | – | 0.02% | 328 |
|
|
2024
Q2 | $374K | Hold |
1,809
| – | – | 0.02% | 310 |
|
|
2024
Q1 | $490K | Hold |
1,809
| – | – | 0.03% | 283 |
|
|
2023
Q4 | $428K | Hold |
1,809
| – | – | 0.03% | 294 |
|
|
2023
Q3 | $355K | Sell |
1,809
-67
| -4% | -$13.8K | 0.02% | 304 |
|
|
2023
Q2 | $394K | Hold |
1,876
| – | – | 0.04% | 224 |
|
|
2023
Q1 | $379K | Hold |
1,876
| – | – | 0.04% | 216 |
|
|
2022
Q4 | $409K | Sell |
1,876
-17
| -0.9% | -$3.71K | 0.04% | 205 |
|
|
2022
Q3 | $373K | Buy |
1,893
+18
| +1% | +$3.89K | 0.13% | 104 |
|
|
2022
Q2 | $401K | Buy |
1,875
+66
| +4% | +$16.1K | 0.13% | 105 |
|
|
2022
Q1 | $514K | Hold |
1,809
| – | – | 0.14% | 102 |
|
|
2021
Q4 | $682K | Hold |
1,809
| – | – | 0.26% | 50 |
|
|
2021
Q3 | $747K | Hold |
1,809
| – | – | 0.34% | 42 |
|
|
2021
Q2 | $669K | Hold |
1,809
| – | – | 0.3% | 46 |
|
|
2021
Q1 | $524K | Hold |
1,809
| – | – | 0.26% | 53 |
|
|
2020
Q4 | $452K | Hold |
1,809
| – | – | 0.22% | 56 |
|
|
2020
Q3 | $410K | Hold |
1,809
| – | – | 0.24% | 54 |
|
|
2020
Q2 | $315K | Hold |
1,809
| – | – | 0.2% | 61 |
|
|
2020
Q1 | $228K | Hold |
1,809
| – | – | 0.16% | 68 |
|
|
2019
Q4 | $276K | Hold |
1,809
| – | – | 0.2% | 71 |
|
|
2019
Q3 | $239K | Hold |
1,809
| – | – | 0.2% | 73 |
|
|
2019
Q2 | $257K | Hold |
1,809
| – | – | 0.22% | 73 |
|
|
2019
Q1 | $263K | Hold |
1,809
| – | – | 0.24% | 66 |
|
|
2018
Q4 | $205K | Hold |
1,809
| – | – | 0.19% | 70 |
|
|
2018
Q3 | $243K | Hold |
1,809
| – | – | 0.2% | 69 |
|
|
2018
Q2 | $203K | Buy |
+1,809
| New | +$196K | 0.18% | 84 |
|
|
2017
Q1 | – | Sell |
-2,694
| Closed | -$205K | – | 87 |
|
|
2016
Q4 | $205K | Buy |
+2,694
| New | +$205K | 0.21% | 72 |
|
Other funds holding CRL
AI
Bryn Mawr Capital Management's CRL Position: Q2 2026 in Review
Bryn Mawr Capital Management held its Charles River Laboratories (CRL) position steady in Q2 2026 at 1,809 shares worth $410K. The position accounts for 0.02% of the portfolio, ranked #323.
Bryn Mawr Capital Management first reported a position in CRL in Q4 2016 and has held it in 34 quarters since. The position peaked at $747K in Q3 2021. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Bryn Mawr Capital Management held 1,809 shares of Charles River Laboratories worth $410K as of Q2 2026.
- Bryn Mawr Capital Management left its Charles River Laboratories share count unchanged in Q2 2026.
- Charles River Laboratories made up 0.02% of Bryn Mawr Capital Management's portfolio in Q2 2026, its #323 holding.
- Bryn Mawr Capital Management first reported a position in Charles River Laboratories in Q4 2016 and has held it in 34 quarters since.
- Bryn Mawr Capital Management's Charles River Laboratories position peaked at $747K in Q3 2021.
- 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Bryn Mawr Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.